Navigation Links
TAK-390MR Phase 3 data presented at Digestive Disease Week
Date:5/19/2008

SAN DIEGO, Calif. May 18, 2008 TAP Pharmaceutical Products Inc. today reported results from three pivotal Phase 3 studies evaluating investigational new drug TAK-390MR, the first proton pump inhibitor (PPI) with an innovative dual delayed release technology, in healing patients with erosive esophagitis (EE) and in maintenance of healed EE. The data were presented at the Digestive Disease Week (DDW) annual meeting in San Diego.

The innovative dual delayed release technology delivers TAK-390MR in two separate releases, which is a first in the PPI class and makes TAK-390MR a very interesting potential future treatment option, said Dr. David Peura, professor of medicine, University of Virginia Health System, past president of the American Gastroenterological Association.

Data from the two separate EE healing studies demonstrated that patients treated with TAK-390MR 60 mg and 90 mg experienced higher overall healing after eight weeks, versus patients taking lansoprazole 30 mg. In addition, data from a six-month maintenance of healed EE study demonstrated that patients treated with TAK-390MR 30 mg and 60 mg experienced statistically significant overall maintenance and symptom relief over placebo.

Healing of Erosive Esophagitis Studies

TAK-390MR was compared to lansoprazole in two identically designed, double-blind, randomized, controlled trials in patients with confirmed EE. A total of 4,092 patients were enrolled in the two global studies. The primary objective was to evaluate overall healing rates over eight weeks after once-daily administration of TAK-390MR 60 mg or 90 mg or lansoprazole 30 mg. The results for each study were analyzed using life table and crude rate methods.

Results from these trials demonstrated that TAK-390MR 60 mg and 90 mg produced consistently high healing rates for patients with EE. In one study, the life table analysis showed that 93 percent and 95 percent of TAK-390MR patients (60 mg a
'/>"/>

Contact: Kelly Thornicroft
kthronicroft@wcpglobal.com
773-405-4515
WeissComm Partners
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Ovation further advances development pipeline with new phase III epilepsy study
2. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
3. Mannatech Launches Phase One of New Sales and Training Tools
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Manic phase of bipolar disorder benefits from breast cancer medication
6. ARIZONA METH PROJECT Unveils Arizonas Anti-Meth Youth Pledge and Kicks Off Phase Two of Public Awareness Campaign
7. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
8. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R)
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 22, 2014 During the ... fresh water supply runs dangerously low, Southern Oregon’s water ... Oregon’s rivers, despite the lowest mountain snow pack on ... late summer and early autumn.* That was the observation ... the new book “Hiking Southern Oregon,” during an interview ...
(Date:10/22/2014)... Healthcare professionals who are looking ... at home or on-the-go via laptops, tablets or ... new, premium Seminar-on-Demand CE courses. The new courses ... 2,000 hours of CE course offerings, allowing ... With such a diverse library, there’s something for ...
(Date:10/22/2014)... are only 24 hours in a day, that doesn’t seem to ... within their busy schedules for exercise and fitness. Fortunately, one does ... in shape. Here are five ways you can reach your fitness ... Your Commute , Consider riding a bike or taking the bus ... routine. If you must use your car to get to work, ...
(Date:10/22/2014)... 2014 Richard Carlson, Managing Partner of ... with over 25 years experience. Mr. Carlson is ... areas related to EDI, B2B Commerce, RFID and Internet/Intranet ... Advisory Board member for Pharmaceutical Commerce Magazine and a ... Group is a management and technology consulting firm focused ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... may be showing a genetic propensity for obesity as toddlers, ... been linked to increased body fat, but the same genes ... the researchers said. At 1 year, kids with these ... 3, however, these genes were linked to excessive weight gain, ...
Breaking Medicine News(10 mins):Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2
... In this unstable economic,environment characterized by zero profit ... the,bio/pharma marketplace, retaining your most-valued customers is the ... from web interactions,and early warning systems to complaint ... superior customer experience. , ...
... help businesses assess the health and value of a website , ... ... agency, has launched a new website tool called the eValuator ... the health and value of their website, simply by entering the website ...
... antibiotic may reduce the frequency of exacerbations in patients ... by as much as 35 percent, according to a ... effect of low-dose macrolide therapy, reducing exacerbation frequency and ... of the paper, Terence A. R. Seemungal, Ph.D., and ...
... 2008) While the U.S. AIDS epidemic simmers largely unnoticed ... HIV testing continues to fuel its spread, HIV researchers ... with HIV last year, and, nationwide, 50-to-70 percent of ... do not know they are infected. ,Guidelines issued ...
... (NMQF) today applauded the American Medical Association,s recent decision to ... physician and patient advocates to join the Forum in encouraging ... , "Physicians and lawyers -- even politicians -- ... Chief Executive Officer of the Forum. "It,s long past time ...
... 20 /PRNewswire/ Bayer HealthCare,has donated hundreds of food items ... response to an urgent call from Governor Jon Corzine ... state,s food banks. , ... Mary Lou Panzano, director, US Internal Communications, and Anne ...
Cached Medicine News:Health News:Creating Brand Advocates by Delivering the Superior Total Customer Experience 2Health News:Bartlett Communications Launches Free Website Evaluation Tool for Small to Mid-Sized Businesses 2Health News:Long-term antibiotics reduce COPD exacerbations, raise questions 2Health News:Long-term antibiotics reduce COPD exacerbations, raise questions 3Health News:Despite national guidelines, private insurers, ER, federal and state agencies fail to routinely test for HIV 2Health News:Despite national guidelines, private insurers, ER, federal and state agencies fail to routinely test for HIV 3Health News:Despite national guidelines, private insurers, ER, federal and state agencies fail to routinely test for HIV 4Health News:Despite national guidelines, private insurers, ER, federal and state agencies fail to routinely test for HIV 5Health News:National Minority Quality Forum Applauds AMA's Health Insurer Code of Conduct 2Health News:Bayer HealthCare Donates Hundreds of Food Items to Community Food Bank of New Jersey in Response to Governor's Plea to Help the State's Population in Need 2
(Date:10/22/2014)... , October 22, 2014 ... ), a clinical-stage pharmaceutical company focused on the ... positive top-line clinical results from its Phase IIa ... insulin capsules, to treat type 1 diabetes. The trial ... under a U.S. Food and Drug ...
(Date:10/22/2014)... Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the second fiscal quarter ... , Revenues of $53.9 million, up 18% over ... $0.24, up 33% over last year,s comparable quarter. ... Veterinary Reference Laboratories (AVRL) of $3.5 million, up 50% ...
(Date:10/22/2014)... -- InVivo Therapeutics Holdings Corp. (OTCQB: NVIV) based in ... cord injury (SCI) treatment with their novel Neuro-Spinal Scaffold. ... regrowth in the spinal cord area when cells are ... polymer, the scaffold ultimately breaks down to water and ... NVIV has recently attracted significant investor attention with the ...
Breaking Medicine Technology:Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3
... EAST RUTHERFORD, N.J., Jan. 7, 2011 Cambrex Corporation ... January 17, Shawn Cavanagh will join the Company as ... Steve Klosk, President and Chief Executive Officer. ... contract manufacturing operations, including the related sales, marketing and ...
... PARK, Ill., Jan. 7, 2011 Partners In Health ... its philanthropic foundation, the Abbott Fund, today announced a ... the longstanding problem of severe malnutrition in Haiti. Together, ... production facility that will allow Haitians to produce locally-sourced, ...
Cached Medicine Technology:Shawn P. Cavanagh Appointed Chief Operating Officer of Cambrex 2Partners In Health, Abbott and the Abbott Fund Unite to Combat Severe Childhood Malnutrition in Haiti 2Partners In Health, Abbott and the Abbott Fund Unite to Combat Severe Childhood Malnutrition in Haiti 3Partners In Health, Abbott and the Abbott Fund Unite to Combat Severe Childhood Malnutrition in Haiti 4
VascoStim B 2/5F is a bipolar temporary pacing lead with a balloon. It can be placed easily by the resistance of the inflated balloon in the blood flow....
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
Medicine Products: